For more than two years it had the entirety of the market for weight-loss drugs to itself. By 2023 sales of Wegovy had ...

Medicare Part D will cover popular weight loss drugs like Wegovy and Ozempic starting in 2026, with copays capped at $50 per ...

FDA-approved weight loss medications include injections (Wegovy®, Zepbound®, etc.) and pills, like Qsymia® and Xenical®. Most ...

Target has expanded its protein and supplement sections as GLP-1 drugs like Ozempic reshape shopping habits, driving demand ...

Novo Nordisk said on Friday the European Medicines Agency's committee had issued a positive opinion for a higher dose of its ...

Eli Lilly said its next generation weight-loss drug retatrutide resulted in significant weight loss and reduced knee pain in ...

In an added benefit, more than one in eight people taking the highest dose of Retratrutide were completely free of arthritic ...

The weight-loss drug market is booming, with biotech firms racing to secure their place in a lucrative sector currently ...

The explosive rise of drugs like Ozempic and Mounjaro is shifting consumption patterns, health outcomes and pushing pharmaceutical giants into trillion-dollar valuations.

Online telehealth company Hims and Hers Health is launching its weight-loss membership and treatment plans in the United ...

A weight loss drug dubbed the "triple G" drug for its effectiveness in mimicking three hunger-regulating hormones showed promising results in new data released Thursday by its maker, Eli Lilly.

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug.